

Bronnen Factsheet Chronische Nierschade - deel 1, Nieren en chronische nierschade

¹ Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and systatin C. *N Engl J Med* 2012; 367(1):20-9.

² Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009; 150(9):604-12.

Bronnen Factsheet Chronische Nierschade - deel 2, Oorzaken van chronische nierschade

¹ Kidney Disease Improving Global Outcomes (KDIGO). Clinical practice guideline for the evaluation and management of chronic kidney disease, chapter 3: Management of progression and complications of CKD. *Kidney Int Suppl* 2013; 3(1):73–90.

² Plantinga LC, Crews DC, Coresh J, Miller ER, Saran R, Yee J, et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. *Clin J Am Soc Nephrol* 2010; 5:673–82.

³ Meer van der V, Wielders HPM, Grootendorst DC, Kanter de J, Sijpkens YWJ, Assendelft WJJ, et al. Chronic kidney disease in patients with diabetes mellitus type 2 or hypertension in general practice. *Br J Gen Pract* 2010; 60(581):884-90.

⁴ Verhave JC, Hillege HL, Burgerhof JGM, Janssen WMT, Gansevoort RT, Navis, et al. Sodium intake affects urinary albumin excretion especially in overweight subjects. *J Intern Med* 2004; 256(4):324–30.

⁵ Lambers Heerspink HJ, Hotlkamp FA, Parving HH, Navis GJ, Lewis JB, Graeff de PA, et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. *Kidney Int* 2012; 82(3):330-7

⁶ Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Lambers Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and Prevention. *Lancet* 2013; 382(9889):339-52.

⁷ Carter BD, Abnet CC, Feskanich D, Freedman ND, Hartge P, Lewis CE, et al. Smoking and mortality - Beyond established causes. *N Engl J Med* 2015; 372:631-40.

⁸ Grauw de WJC, Kaasjager HAH, Bilo HJG, Faber EF, Flikweert S, Gaillard CAJM, et al. Landelijke Transmurale Afspraak Chronische nierschade. *Huisarts Wet* 2009; 52(12):586-97.

⁹ East Midlands Public Health Observatory (EMPHO), NHS Kidney Care. Report Kidney disease: Key facts and figures. 2010.

Bronnen Factsheet Chronische Nierschade - deel 3, Stadia chronische nierschade

¹ Matsushita K, Velde van der M, Astor BC, Woodward M, Levey AS, Jong de PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis of general population cohorts. *Lancet* 2010; 375(9731):2073-81.

² Kidney Disease Improving Global Outcomes (KDIGO). Clinical practice guideline for the evaluation and management of chronic kidney disease, Chapter 1: Definition, and classification of CKD. *Kidney Int Suppl* 2013; 3(1):19-62.

³ Gansevoort RT. Naar een nieuwe CKD classificatie. *NTvN* 2011; 1(3):8-11.

⁴ Kidney Disease Improving Global Outcomes (KDIGO). Clinical practice guideline for the evaluation and management of chronic kidney disease, chapter 2: Definition, identification, and prediction of CKD progression. *Kidney Int Suppl* 2013; 3(1):63–72.

⁵ The United States Renal Data System (USRDS). Annual data report: Cardiovasculair disease in patients with chronic kidney disease. 2013; 1:73-82. http://www.usrds.org/2013/pdf/v1_ch4_13.pdf

⁶ Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Lambers Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and Prevention. *Lancet* 2013; 382(9889):339-52.

- ⁷ Jha V, Garcia-Garcia G, Iseki K, Naicker S, Plattner B, Saran R, et al. Chronic kidney disease: global dimension and perspectives. *Lancet* 2013; 382(9888):260-72.
- ⁸ Coresh J, Selvin E, Stevens LA, Manzi J, Kusek W, Eggers P, et al. Prevalence of chronic kidney disease in the United States. *J Am Med Assoc* 2007; 298(17):2038-47.
- ⁹ Jong de PE, Velde van der M, Gansevoort RT, Zoccali C. Screening for chronic kidney disease: where does Europe go? *Clin J Am Soc Nephrol* 2008; 3(2):616-23.
- ¹⁰ Wetzels JFM, Kiemeny LALM, Swinkels DW, Willems HL, Heijer den M. Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study. *Kidney Int* 2007; 72(5):632-37.
- ¹¹ Levey AS, Jong de PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. *Kidney Int* 2011; 80:17–28.
- ¹² Kidney Disease Improving Global Outcomes (KDIGO). Clinical practice guideline for the evaluation and management of chronic kidney disease, chapter 3: Management of progression and complications of CKD. *Kidney Int Suppl* 2013; 3(1):73–90.
- ¹³ Plantinga LC, Crews DC, Coresh J, Miller ER, Saran R, Yee J, et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. *Clin J Am Soc Nephrol* 2010; 5: 673–82.
- ¹⁴ Meer van der V, Wielders HPM, Grootendorst DC, Kanter de J, Sijpkens YWJ, Assendelft WJJ, et al. Chronic kidney disease in patients with diabetes mellitus type 2 or hypertension in general practice. *Br J Gen Pract* 2010; 60(581):884-90.
- ¹⁵ Rijksinstituut voor Volksgezondheid en Milieu (RIVM), Ministerie van Volksgezondheid, Welzijn en Sport (VWS). VTV 2014 [http://www.eengezondernederland.nl/Trends in de toekomst/Ziekten#cat-7](http://www.eengezondernederland.nl/Trends%20in%20de%20toekomst/Ziekten#cat-7).
- ¹⁶ Rijksinstituut voor Volksgezondheid en Milieu (RIVM). <http://www.nationaalkompas.nl/gezondheidsdeterminanten/persoonsgebonden/bloeddruk/hoeveel-mensen-hebben-een-verhoogde-bloeddruk/>

Bronnen Factsheet Chronische Nierschade - deel 4, Klachten en behandeling chronische nierschade

- ¹ Grauw de WJC, Kaasjager HAH, Bilo HJG, Faber EF, Flikweert S, Gaillard CAJM, et al. Landelijke Transmurale Afspraak Chronische nierschade. *Huisarts Wet* 2009; 52(12):586-97.
- ² Rensma PL, Hagen EC, Bommel van EFH, Wetzels JFM, Kaasjager HAH, Wee ter PM, et al. Richtlijn voor de behandeling van patiënten met Chronische Nierschade (CNS). 2009.

Bronnen Factsheet Chronische Nierschade - deel 5, Vroeg opsporen en voorkomen achteruitgang chronische nierschade

- ¹ Grauw de WJC, Kaasjager HAH, Bilo HJG, Faber EF, Flikweert S, Gaillard CAJM, et al. Landelijke Transmurale Afspraak Chronische nierschade. *Huisarts Wet* 2009; 52(12):586-97.
- ² Rensma PL, Hagen EC, Bommel van EFH, Wetzels JFM, Kaasjager HAH, Wee ter PM, et al. Richtlijn voor de behandeling van patiënten met Chronische Nierschade (CNS). 2009.
- ³ Scherpbier ND. Proefschrift Optimising Chronic Kidney Disease management in primary care. Is shared care the answer? 2013; ISBN/EAN 978-90-9027410-2.
- ⁴ Blijderveen van JC, Straus SM, Zietse R, Stricker BH, Sturkenboom MC, Verhamme KM. A population-based study on the prevalence and incidence of chronic kidney disease in the Netherlands. *Int Urol Nephrol* 2014; 46(3):583–92.
- ⁵ Gansevoort RT, Jong de PE. The case for using albuminuria in staging chronic kidney disease. *J Am Soc Nephrol* 2009; 20(3):465-68.
- ⁶ Meer van der V, Wielders HPM, Grootendorst DC, Kanter de J, Sijpkens YWJ, Assendelft WJJ, et al. Chronic kidney disease in patients with diabetes mellitus type 2 or hypertension in general practice. *Br J Gen Pract* 2010; 60(581):884-90.

⁷ Özyilmaz A, Jong de PE, Gansevoort RT. Screening for chronic kidney disease can be of help to prevent atherosclerotic end-organ damage. *Nephrol Dial Transpl* 2012; 27(11):4046-52.

⁸ Scheven L, Velde van der M, Lambers HJ, Heerspink L, Jong de PE, Gansevoort RT. Isolated microalbuminuria indicates a poor medical prognosis. *Nephrol Dial Transplant* 2013; 28(7):1794-801.

⁹ Jha V, Garcia-Garcia G, Iseki K, Naicker S, Plattner B, Saran R, et al. Chronic kidney disease: global dimension and perspectives. *Lancet* 2013; 382(9888):260-72.

Bronnen Factsheet Chronische Nierschade - deel 6, Nierfalen en behandeling

¹ Hsu CY, Chertow GM, McCulloch CE, Fan D, Ordoñez JD, Go AS. Nonrecovery of kidney function and death after acute on chronic renal failure. *Clin J Am Soc Nephrol* 2009; 4(5):891-8.

² ERA-EDTA Registry: ERA-EDTA Registry Annual Report 2012. Academic Medical Center, Department of Medical Informatics, Amsterdam, The Netherlands, 2014.

³ Kidney Disease Improving Global Outcomes (KDIGO). Clinical practice guideline for the evaluation and management of chronic kidney disease, chapter 5: Referral to specialists and models of care. *Kidney Int Suppl* 2013; 3(1):112-9.

⁴ Tattersall J, Dekker F, Heimbürger O, Jager KJ, Lameire N, Lindley E, et al. When to start dialysis: updated guidance following publication of the Initiating Dialysis Early and Late (IDEAL) study. *Nephrol. Dial. Transplant.* 2011; 26(7):2082-6.

⁵ NfN, Kwaliteitscommissie NfN, V&VN Dialyse en Nefrologie, DNN, VMWN en HMI. Multidisciplinaire richtlijn predialyse, update febr 2011.

⁶ Biowetenschappen en Maatschappij (BWM). Nierdonatie bij leven. Je nier of mijn leven! Jaargang 33, Cahier 3, 2014. ISBN 9789073196759.

⁷ Data verkregen van REgistratie Nierfunctieervanging Nederland. www.renine.nl.

⁸ Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Lambers Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and Prevention. *Lancet* 2013; 382(9889):339-52.

⁹ Rapportage Nierstichting d.d. 5 april 2018, Kosten nierfunctieervangende behandelingen.

Bronnen Factsheet Chronische Nierschade - deel 7, Niertransplantatie, donatie en wachtlijsten

¹ Summers DM, Watson CJ, Pettigrew GJ, Johnson RJ, Collett D, Neuberger JM, Bradley JA. Kidney donation after circulatory death (DCD): state of the art. *Kidney Int* 2015. doi: 10.1038/ki.2015.88.

² Data verkregen van Nederlandse Transplantatie Stichting (NTS) <http://www.transplantatiestichting.nl> uit jaarverslagen.

³ Newsletter Transplant. International figures on donation and transplantation - 2013. 2014; 19(1):1-94.

⁴ Abecassis M, Bartlett ST, Collins AJ, Davis CL, Delmonico FL, Friedewald JJ, et al. Kidney Transplantation as Primary Therapy for End-Stage Renal Disease: A National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQI™) Conference. *Clin J Am Soc Nephrol* 2008; 3(2):471-80.

⁵ Liem YS, Wong JB, Winkelmayer WC, Weimar W, Wetzels JF, Charro de FT, et al. Quantifying the benefit of early living-donor renal transplantation with a simulation model of the Dutch renal replacement therapy population. *Nephrol Dial Transplant* 2012; 27(1):429-34.

⁶ Bemelman FJ, Berge ten RJM. Late complicaties na niertransplantatie. *Ned Tijdschr Geneesk* 2008; 152(23):1317-21.

⁷ Mange KC1, Weir MR. Preemptive renal transplantation: why not? *Am J Transplant.* 2003 Nov;3(11):1336-40.

⁸ Meier-Kriesche HU, Schold JD. The impact of pretransplant dialysis on outcomes in renal transplantation. *Semin Dial* 2005; 18(6):499-504.

⁹ Biowetenschappen en Maatschappij (BWM). Nierdonatie bij leven. Je nier of mijn leven! Jaargang 33, Cahier 3, 2014. ISBN 9789073196759.

¹⁰ Schipper K, Abma TA, Koops C, Bakker I, Sanderman R, Schroevers MJ. Sweet and sour after renal transplantation: A qualitative study about the positive and negative consequences of renal transplantation. *Brit J Health Psych* 2014; 19(3):580-91.

¹¹ Lentine KL, Patel A. Risks and outcomes of living donation. *Adv Chronic Kidney Dis* 2012; 19(4):220-8.

¹² Lam NN, Lentine KL, Levey AS, Kasiske BL, Garg AX. Long-term medical risks to the living kidney donor. *Nat Rev Nephrol* 2015; 11(7):411-9.

¹³ Gaston RS, Kumar V, Matas AJ. Reassessing medical risk in living kidney donors. *J Am Soc Nephrol* 2015; 26(5):1017-9.

¹⁴ Hodac-Pannekeet MM, Sijpkens YWJ, Berkhout-Byrne NC, Janssen L, Zengerink M, Jans I, et al. Multidisciplinaire richtlijn predialyse 2011.

¹⁵ Mossevelde van E, Koekenbier M, ÉénVandaag Opiniepanel. Onderzoek: Meerderheid voor nieuw donorsysteem. 2014.

¹⁶ <https://www.donorregister.nl>.

¹⁷ <http://linkis.com/statline.cbs.nl> > Stat/v5VfU.

¹⁸ Coördinatiegroep Orgaandonatie (CGOD). Brief aan Ministerie van VWS. Dd 27 februari 2015.

¹⁹ Coördinatiegroep Orgaandonatie. Masterplan Orgaandonatie, de vrijblijvendheid voorbij. 2008.

²⁰ 18 jarigen zeggen vaker 'Ja' - hoe vaak is vaak? <http://2mhclub.nl/> 2015.

Bronnen Factsheet Chronische Nierschade - deel 8, Dialyse

¹ Data verkregen van REgistratie Nierfunctieervanging Nederland. www.renine.nl.

² Fernández-Reyes MJ, Bajo MA, Del Peso G, Ossorio M, Díaz R, Carretero B, et al. The influence of initial peritoneal transport characteristics, inflammation, and high glucose exposure on prognosis for peritoneal membrane function. *Perit Dial Int* 2012; 32(6):636-44.

³ Kolesnyk I, Dekker FW, Boeschoten EW, Krediet RT. Time-dependent reasons for peritoneal dialysis technique failure and mortality. *Perit Dial Int* 2010; 30(2):170-7.

⁴ Jager KJ, Ocaik G, Drechsler C, Caskey FJ, Evans M, Postorino M, et al. The EQUAL study: a European study in chronic kidney disease stage 4 patients. *Nephrol Dial Transplant* 2012; 27:Suppl 3:iii:27-31.

⁵ Teixeira JP, Combs SA, Teitelbaum I. Peritoneal dialysis: update on patient survival. *Clin Nephrol* 2015; 83(1):1-10.

⁶ Huisman RM. Dialyse bij ouderen. *Ned Tijdschr Geneesk* 1997; 141(5):229-33.

⁷ Wang AY, Ninomiya T, Al-Kahwa A, Perkovic V, Gallagher MP, Hawley C, et al. Effect of hemodiafiltration or hemofiltration compared with hemodialysis on mortality and cardiovascular disease in chronic kidney failure: a systematic review and meta-analysis of randomized trials. *Am J Kidney Dis* 2014; 63(6):968-78.

⁸ Nefrovisie, zicht op nierzorg. www.nefrovisie.nl.

Bronnen Factsheet Chronische Nierschade - deel 9, Nieren en zout

¹ Gezondheidsraad. Richtlijnen goede voeding 2015. Den Haag: Gezondheidsraad, 2015; publicatie nr 2015/24. ISBN 978-94-6281-089-1.

² Rossum van CTM, Buurma-Rethans EJM, Fransen HP, Verkaik-Kloosterman J, Hendriksen MAH. Zoutconsumptie van kinderen en volwassenen in Nederland, resultaten uit de Voedselconsumptiepeiling 2007-2010. Rijksinstituut voor Volksgezondheid en Milieu, 2012.

³ Hendriksen M, Etemad Z., Bogaard van den CHM, A van der DL. Zout-, jodium- en kaliuminname 2015: Voedingsstatusonderzoek bij volwassenen uit Doetinchem. Rijksinstituut voor Volksgezondheid en Milieu, 2016. RIVM Briefrapport 2016-0081.

⁴ <http://www.worldactiononsalt.com> > salthealth > factsheets > stomach

⁵ <http://www.worldactiononsalt.com> > salthealth > factsheets > osteoporosis

⁶ Hendriksen MAH, Over EAB, Navis G, Joles J, Hoorn EJ, Gansevoort RT *et al.* Limited salt consumption reduces the incidence of chronic kidney disease: a modeling study. *J Public Health* 2018; doi: 10.1093/pubmed/fox178. De getallen in deze factsheet zijn afgeleid van de getallen over 20 jaar.

⁷ Hendriksen MAH. Proefschrift: Public health impact of salt reduction. Wageningen University 2015. ISBN 978-94-6257-546-2. De getallen in deze factsheet zijn afgeleid van de getallen over 20 jaar.

⁸ Bibbins-Domingo K, Chertow GM, Coxson PG, Moran AE, Lightwood JM, Pletcher MJ *et al.* Reductions in cardiovascular disease projected from modest reductions in dietary salt. *N Engl J Med* 2010; 362(7):590-99.

⁹ Doorenbos CJ, Vermeij CG. Danger of salt substitutes that contain potassium in patients with renal failure. *BMJ* 2003; 326(7379):35-6.

¹⁰ RIVM rapport 350022002/2013 Natrium en verzadigd vet in beeld; veranderingen in de samenstelling van voedingsmiddelen in 2012.

¹¹ Warenwetbesluit Meel en Brood, 13 juli 2012.

Bronnen Factsheet Chronische Nierschade - deel 10, Nieren en medicijnen

¹ Scherpbier ND. Proefschrift Optimising Chronic Kidney Disease management in primary care. Is shared care the answer? 2013; ISBN/EAN 978-90-9027410-2.

² Koster ES, Philbert D, Noordam M, Winters NA, Blom L, Bouvy ML. Availability of information on renal function in Dutch community pharmacies. *Int J Clin Pharm* 2016; 38(4):797-801.

³ Pharmaceutisch Weekblad: 'dossier nieren'. Pharmaceutisch Weekblad 2016, jaargang 151.

⁴ Smits E, Houben E, Smet de PAGM, Szerencsi K, Herk-Sukel van MPP, Herings RMC, et al. The availability of information on impaired renal function in the community pharmacy, a descriptive pilot study. *J Nephrol Renal Ther* 2016; 2:003.

⁵ Floor-Schreuderling A, Heringa M. Klinische relevantie van medisch farmaceutische beslisregels inzake laboratoriumwaarden in openbare apotheken. SIR Institute for Pharmacy Practice and Policy, 2015.

⁶ Heringa M, Steeg van de-Gompel van CH, Bouvy ML. Medisch-farmaceutische beslisregels en nierfunctie meten in de apotheek: wat levert het op? Nederlands Platform voor Farmaceutisch Onderzoek. 2017;2:a1638

⁷ Leendertse AJ, Egberts ACG, Stoker LJ, Bemt van den PMLA. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. *Arch Intern Med* 2008; 168(17):1890-96.

⁸ Leendertse AJ, Dijk van EA, Smet de PAGM, Egberts TCG, Bemt van den PMLA. Contribution of renal impairment to potentially preventable medication-related hospital admissions. *Ann Pharmacother* 2012; 46(5):625-33.

⁹ Helldén A, Bergman U, Euler von M, Hentschke M, Odar-Celderlöf I, Öhlén G. Adverse drug reactions and impaired renal function in elderly patients admitted to the emergency department. *Drug Aging* 2009; 26(7):595-606.

¹⁰ Nederlands doseringsadvies bij verminderde nierfunctie. KNMP Kennisbank, 2005.

¹¹ Data verkregen van REgistratie Nierfunctievervanging Nederland. www.renine.nl.

¹² Peter WL. Management of polypharmacy in dialysis patients. *Semin Dial* 2015; 28(4):427-32.